Mazdutide Peptide
Price range: $75.00 through $99.00
Research-grade Mazdutide (IBI362/LY3305677) is a synthetic 39-amino-acid dual-agonist peptide targeting GLP-1R and GCGR receptors, designed for controlled in vitro and preclinical investigations of dual incretin receptor signaling, cardiometabolic pathway analysis, and related metabolic biology research models. For Research Use Only. Not for human use.
Discount per Quantity
| Quantity | 5 – 9 | 10 + |
|---|---|---|
| Discount | 5% | 10% |
| Price | $71.25 | $67.50 |
Orders over $200: FREE USPS Priority shipping.
- >99% purity — HPLC + MS verified
- Cold-pack insulated mailers
- Discreet US shipping (2–5 days)
- COA available on request
Research Use Only. Not for human consumption. Sold strictly for laboratory and research use.
Mazdutide is an investigational unimolecular dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), developed as an analog of oxyntomodulin. It combines GLP-1R and GCGR receptor activation mechanisms, making it a subject of ongoing preclinical and clinical research into dual-receptor incretin biology. This product is supplied as a research-grade lyophilized powder synthesized under strict quality controls with full analytical documentation. For Research Use Only. Not for human use.
Key Scientific Attributes
- High-purity Mazdutide (≥98% by HPLC/MS, acetate salt form)
- Verified 39-amino-acid sequence based on oxyntomodulin scaffold with modifications for dual GLP-1R/GCGR agonism
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, and receptor-binding assays (GLP-1R/GCGR EC50)
- Manufactured in GMP-aligned, ISO-compliant facilities
- Suitable for dual-agonist receptor signaling pathway studies and incretin biology research
Research-Referenced Attributes (Based on published preclinical and clinical literature; not therapeutic claims.)
- Dual GLP-1R/GCGR receptor activation profile studied in published Phase 2 and Phase 3 trials (GLORY program, DREAMS program); see peer-reviewed sources for full data
- Receptor pharmacology data available in published literature, including studies in cardiometabolic, incretin, and hepatic fat metabolism research models
- Investigated in NAFLD/MASH models and neurological research contexts involving glutamate receptor pathways
- Favorable in vitro tolerability profile reported across published preclinical literature
Why Researchers Choose Nationwide Peptides Mazdutide
- Exact clinical-sequence match to IBI362/LY3305677 with verified dual-receptor binding affinity
- High potency for GLP-1R/GCGR in vitro studies among research-grade suppliers
- Transparent analytical data (HPLC ≥98%, MS confirmation)
- Competitive research pricing with bulk options available
| SKU | mazdutide |
|---|---|
| Category | Peptides |
| Purity | >99% (HPLC + MS verified) |
| Form | Lyophilized powder |
| Origin | Synthesized in the USA |
Certificate of Analysis
Every lot is verified by reverse-phase HPLC for purity and by mass spectrometry for identity. A current COA is available on request — email sales@limitlesslifenootropics.st with the lot number printed on your vial.
- HPLC purity: >99%
- Identity confirmed by ESI-MS
- Lyophilized, sterile-filtered solutions where applicable
- Stored at −20°C until shipment
Shipping & handling
Orders placed before 2pm CT ship the same business day in cold-pack insulated mailers. USPS Priority delivery in 2–5 business days. Free shipping on US orders over $200.
Frequently asked questions
How should I reconstitute this peptide?
Use bacteriostatic water for short-term lab storage. Direct the diluent down the side of the vial, swirl gently — do not shake.
What is the shelf life?
Lyophilized peptide stored at −20°C is stable for 24+ months. Reconstituted peptide should be refrigerated and used within 2–4 weeks.
Do you ship internationally?
We currently ship within the United States only. International researchers should contact our bulk team for institutional quotes.
Frequently bought together
Reviews
There are no reviews yet.